Citi Keeps Their Buy Rating on Boston Scientific (BSX)

In a report released today, Joanne Wuensch from Citi maintained a Buy rating on Boston Scientific, with a price target of $61.00.

Claim 55% Off TipRanks

• Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
• Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks

According to TipRanks, Wuensch is a 4-star analyst with an average return of 2.5% and a 54.64% success rate. Wuensch covers the Healthcare sector, focusing on stocks such as Abbott Laboratories, Baxter International, and Edwards Lifesciences.

In addition to Citi, Boston Scientific also received a Buy from Bank of America Securities’s Travis Steed in a report issued on August 11. However, on July 30, Argus Research downgraded Boston Scientific (NYSE: BSX) to a Hold.

Based on Boston Scientific’s latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $5.44 billion and a net profit of $907 million. In comparison, last year the company earned a revenue of $5.06 billion and had a net profit of $793 million

Based on the recent corporate insider activity of 58 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of BSX in relation to earlier this year. Earlier this month, David Habiger, a Director at BSX bought 2,100.00 shares for a total of $99,918.00.